Kisha Morgan, MD
Pulmonary Disease · Sarasota, FLNPI 1427080910
Payments from drug & device makers
Across 217 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$872
- GSK$717
- Insmed, Inc.$607
- Actelion Pharmaceuticals US, Inc.$574
- Boehringer Ingelheim$408
- AstraZeneca$258
- plus $1K from 24 others
What the payments were for
- Travel & lodging$65514%
- Food & beverage$3,95582%
- Education$2405%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 10 | $872 |
| GSK | 59 | $717 |
| Insmed, Inc. | 26 | $607 |
| Actelion Pharmaceuticals US, Inc. | 21 | $574 |
| Boehringer Ingelheim | 19 | $408 |
| AstraZeneca | 14 | $258 |
| Merck | 8 | $200 |
| Grifols USA, LLC | 5 | $124 |
| United Therapeutics Corporation | 5 | $121 |
| Amgen | 6 | $111 |
| Johnson & Johnson | 5 | $99 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Bayer | 5 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Shionogi Inc | 3 | $62 |
| Philips North America LLC | 3 | $59 |
| Gilead | 3 | $52 |
| Electromed, Inc. | 4 | $50 |
| Pulmonx Corporation | 1 | $50 |
| Verona Pharma, Inc. | 2 | $47 |
| Harmony Biosciences LLC | 2 | $43 |
| Sanofi | 1 | $36 |
| Nabriva Therapeutics, PLC | 2 | $25 |
| Vapotherm Inc | 1 | $22 |
| Mylan Specialty L.p. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
How this compares
$4,851 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 60 | $758,277 |
| AdempasRiociguat | 23 | $345,821 |
| Tyvaso DpiTreprostinil | 12 | $281,788 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 349 | $269,673 |
| Breo ElliptaFluticasone/Vilanterol | 155 | $91,559 |
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $90,290 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $73,727 |
| Ambrisentan | 26 | $51,751 |
| Spiriva RespimatTiotropium Bromide | 41 | $35,810 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $23,769 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $22,974 |
| EliquisApixaban | 21 | $14,942 |
| Arnuity ElliptaFluticasone Furoate | 45 | $14,713 |
| Tadalafil | 18 | $14,261 |
| DuleraMometasone/Formoterol | 33 | $13,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $574 | $758,27760 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $717 | $398,919598 claims |
| BayerAdempas | $71 | $345,82123 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $258 | $82,930118 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $408 | $65,24696 claims |
| PfizerEliquis | $12 | $14,94221 claims |
| MerckDulera | $200 | $13,20333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sarasota
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.